Randomized, Placebo-Controlled Trial of Platelet Glycoprotein IIb/IIIa Blockade With Primary Angioplasty for Acute Myocardial Infarction | Zendy

Sorin J. Brener | Zendy; Lawrence A. Barr | Zendy; J.E.B. Burchenal | Zendy; Stanley Katz | Zendy; Barry S. George | Zendy; Ancil A. Jones | Zendy; Eric David Cohen | Zendy; Phillip C. Gainey | Zendy; Harvey White | Zendy; H. Barrett Cheek | Zendy; Jeffrey W. Moses | Zendy; David J. Moliterno | Zendy; Mark B. Effron | Zendy; Eric J. Topol | Zendy

Open Access

Randomized, Placebo-Controlled Trial of Platelet Glycoprotein IIb/IIIa Blockade With Primary Angioplasty for Acute Myocardial Infarction

Author(s) -

Sorin J. Brener,

Lawrence A. Barr,

J.E.B. Burchenal,

Stanley Katz,

Barry S. George,

Ancil A. Jones,

Eric David Cohen,

Phillip C. Gainey,

Harvey White,

H. Barrett Cheek,

Jeffrey W. Moses,

David J. Moliterno,

Mark B. Effron,

Eric J. Topol

Publication year - 1998

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/01.cir.98.8.734

Subject(s) - medicine , primary angioplasty , myocardial infarction , blockade , cardiology , angioplasty , randomized controlled trial , placebo , abciximab , platelet , percutaneous coronary intervention , receptor , pathology , alternative medicine

The benefit of catheter-based reperfusion for acute myocardial infarction (MI) is limited by a 5% to 15% incidence of in-hospital major ischemic events, usually caused by infarct artery reocclusion, and a 20% to 40% need for repeat percutaneous or surgical revascularization. Platelets play a key role in the process of early infarct artery reocclusion, but inhibition of aggregation via the glycoprotein IIb/IIIa receptor has not been prospectively evaluated in the setting of acute MI.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research